Sofinnova Partners, a European life sciences venture capital firm based in Paris, France, London, UK and Milan, Italy, closed its Digital Medicine Fund, at $200M.
The fund targets three main areas:
- enabling technologies,
- analytics, and
Led by Simon Turner and Edward Kliphuis, the fund firm provides entrepreneurs with financial resources, expertise, and healthcare networks, empowering them to address global healthcare challenges and enhance patient outcomes worldwide.
The firm has already invested in L’école AI, Betteromics, BioCorteX, deepc, and Kiro.
Commenting on the news, Edward Kliphuis said: “In just a few months since launching this strategy, we’ve executed five investments into transformative companies, including Kiro, BioCorteX, deepc, L’école AI, and Betteromics, which are fusing state-of-the-art computational methods with advanced biological innovations. Leveraging Sofinnova’s expertise and network, we serve as allies to digital medicine pioneers, enabling them to secure product-market fit and scale on a global stage.”
Simon Turner added: “We bring Sofinnova’s deep healthcare expertise to entrepreneurs pioneering at the forefront of digital medicine where biology meets tech-industry approaches like rapid product iteration and accelerated commercialization. Our goal is to support innovators developing disruptive solutions for patients and health systems.”
Sofinnova Partners is a European venture capital firm in life sciences, specializing in healthcare and sustainability with over €2.5 Billion under management.